Fennec Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Fennec Pharmaceuticals

12/05/2023 05:01

* Fennec Pharmaceuticals Inc  FENC.OQ  reported a quarterly
adjusted loss of 23 cents​​ per share for the quarter ended in
March. The mean expectation of five analysts for the quarter was
for a loss of 21 cents per share.
    * Revenue was $1.68 million​; analysts expected $1.85
million. 
    * Fennec Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 23 cents​.
    * The mean earnings estimate of analysts had fallen by
about 8% in
the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates 
    * Fennec Pharmaceuticals Inc shares had fallen by 5.0% this
quarter and lost 17.7% so far this year.
    * The company reported a quarterly loss of $6.05 million.
    * Wall Street's median 12-month price target for Fennec
Pharmaceuticals Inc is $16.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
12 at 04:01 a.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.21          -0.23          Missed
 Dec. 31 2022      -0.26          -0.26          Met
 Sep. 30 2022      -0.18          -0.31          Missed
 Jun. 30 2022      -0.14          -0.19          Missed